BioXcel Therapeutics Inc (BTAI) concluded trading on Thursday at a closing price of $0.19, with 9.46 million shares of worth about $1.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.56% during that period and on February 06, 2025 the price saw a loss of about -37.57%. Currently the company’s common shares owned by public are about 42.46M shares, out of which, 41.32M shares are available for trading.
Stock saw a price change of -42.21% in past 5 days and over the past one month there was a price change of -67.45%. Year-to-date (YTD), BTAI shares are showing a performance of -50.09% which decreased to -94.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.27 but also hit the highest price of $4.17 during that period. The average intraday trading volume for BioXcel Therapeutics Inc shares is 1.66 million. The stock is currently trading -44.69% below its 20-day simple moving average (SMA20), while that difference is down -51.19% for SMA50 and it goes to -80.07% lower than SMA200.
BioXcel Therapeutics Inc (NASDAQ: BTAI) currently have 42.46M outstanding shares and institutions hold larger chunk of about 6.34% of that.
The stock has a current market capitalization of $9.26M and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$2.15 in the same period. It has Quick Ratio of 1.81. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BTAI, volatility over the week remained 15.46% while standing at 15.32% over the month.
Stock’s fiscal year EPS is expected to rise by 74.51% while it is estimated to increase by 26.99% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on February 21, 2024 offering a Neutral rating for the stock and assigned a target price range of between $9 and $4 to it. Coverage by Mizuho stated BioXcel Therapeutics Inc (BTAI) stock as a Neutral in their note to investors on August 15, 2023, suggesting a price target of $4 for the stock. On July 17, 2023, Guggenheim Downgrade their recommendations, while on March 10, 2023, Jefferies Downgrade their ratings for the stock with a price target of $22. Stock get a Neutral rating from Goldman on December 01, 2022.
